On March 19, 2026, Picard Medical, Inc. (NYSE American: PMI) announced a significant medical achievement involving the SynCardia Total Artificial Heart. A patient in his twenties, suffering from advanced biventricular heart failure, was successfully bridged to heart transplantation after being supported by the SynCardia device for 119 days. The procedure took place at UCSF Health, where the patient received the artificial heart on November 15, 2025, allowing him to maintain full circulatory support while awaiting a donor heart. This case marks the second successful heart transplant using the SynCardia Total Artificial Heart at UCSF, highlighting the device's critical role in managing patients with severe heart conditions. Dr. Amy G. Fiedler, the Surgical Director of Heart Transplantation at UCSF, expressed satisfaction with the outcome, noting the importance of the partnership with SynCardia in providing life-saving support to patients. Picard Medical's CEO, Patrick NJ Schnegelsberg, emphasized the growing adoption of the Total Artificial Heart technology at leading transplant centers, reflecting the increasing need for advanced mechanical circulatory support for patients facing end-stage heart failure. This development is expected to positively impact the company's stock performance as it showcases the effectiveness of their innovative medical technology.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.